Table 3.
Lung and pancreatic tumor comparison.
| Lung (n = 50) | Pancreas (n = 35) | ||
|---|---|---|---|
| Age at diagnosis (years) | Median (range) | 42 (19-77) | 37 (14-67) |
| Mean ± SD | 43 ± 14.3 | 40 ± 13.9 | |
| Diagnostic delay (years) | Median (range) | 8 (2-22) | 6 (2-19) |
| Mean ± SD | 8.5 ± 6 | 7.1 ± 4.8 | |
| Tumor size (cm) | Median (range) | 5.9 (1.2-10) | 6 (1-25) |
| Mean ± SD | 5.5 ± 2.5 | 6.7 ± 5 | |
| Hyperprolactinemia (%) | 30% | 57% | |
| Other hormones (%)* | Serum elevated levels | 42% | 69% |
| Immunohistochemistry | 8% | 40% | |
| Metastases (%) | 42% | 37% | |
| MEN 1 syndrome | 0 | 18 | |
| Remission (full or partial) (%) | 78% | 69% | |
| Survival rate (%) | 94% | 86% |
*Other hormones include: adrenaline, adrenocorticotropic hormone (ACTH), calcitonin, cortisol, follicle-stimulating hormone (FSH), glucagon, gastrin, insulin, luteinizing hormone (LH), noradrenaline, pancreatic polypeptide (PP), parathormone (PTH), serotonin, somatostatin, thyroid-stimulating hormone (TSH), triiodothyronine (T3) and thyroxine (T4), vasoactive intestinal peptide (VIP).